DiaMedica Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Enrollment Complete in First Two Cohorts of Phase 2 Early-Onset Fetal Growth Restriction Trial; KOL
Enrollment Complete in First Two Cohorts of Phase 2 Early-Onset Fetal Growth Restriction Trial; KOL